|
A chemically-validated-prescription-drug startup a day keeps the FOMO away.
|
Startup of the Year: Daily Dealflow
most promising and innovative startups from around the world.
#DailyDealflow newsletter delivers one seed-stage startup a day, every work day
and is presented by Silicon Valley Bank. |
Valisure
Valisure is a digital pharmacy that chemically validates medications for quality and consistency delivered directly to consumers.
|
|
Valisure is launching the first digital pharmacy to dispense chemically validated medications direct to consumers. Valisure’s Harvard and Yale-trained scientists have developed a novel, laser-based analytical technology that enables them to deliver medications to consumers that are batch-analyzed and validated for quality and consistency. This state-of-the-art process allows Valisure to rigorously validate every batch of prescription medication, over-the-counter drug or supplement it dispenses without adding costs to consumers.
Valisure identifies the primary ingredients, validates the dosage and ensures that the drug-dissolution time is appropriate. This information is relayed in an easy-to-understand certificate of analysis. Valisure’s cutting-edge technology was developed to address rising medication quality concerns over counterfeits, generics and overseas manufacturing in India and China.
Valisure founders Adam Clark-Joseph and David Light, friends since their Yale days, reconnected after Adam suffered serious complications from his anticonvulsant medication due to batch variability. Shocked that no adequate safe guards were in place, they began to grasp the magnitude and pervasiveness of the problem throughout the pharmaceutical industry. They developed Valisure as a solution to bring significant improvements in quality and consistency direct to consumers. Valisure has ISO 17025 accreditation and is DEA and FDA registered.
|
⚙️ Product Stage
First Full Release
|
|
🏭 Industries
E-Commerce, Health and Wellness, Pharmaceuticals
|
|
|
🤑 Fundraising Status
Prefer not to say
|
|
📈 Last Funding Stage
Seed
|
|
💸 Total Funding to Date
$2,200,000
|
|
|
Competitive Advantage
Valisure’s founding team developed a proprietary laser system for the analysis of medications. This patent-pending technology generates high-precision results consistent with industry standard HPLC (High Performance Liquid Chromatography), but retain the high-speed and low-cost advantages of spectroscopy-based analysis. Whereas industry-standard technology often takes a month or more to calibrate a new substance, Valisure’s laser system only takes one day. This state-of-the-art process allows Valisure to rigorously validate every batch of prescription medication, over-the-counter drug or supplement it dispenses. Valisure’s mission is patient advocacy, consumer protection and performing advanced research and development. Valisure is the first American pharmacy to chemically validate and ensure the quality of all its products and to do so at no additional costs to consumers.
|
Contact the Founder:
David Light
|
|
The Daily Dealflow is made possible thanks to the support of our amazing partners.
|
Silicon Valley Bank and its extensive team of early stage startup experts are supporters of startup communities everywhere. Click here to learn more. |
|
|
Do you travel for business? American Airlines® has a free, special offer for our friends – companies who enroll in their Business Extra program can earn up to 600 bonus Business Extra points. The program allows your travelers to earn their AAdvantage® miles while collectively earning Business Extra points for the business.
|
|
|
Startup of the Year is powered by Established, a consultancy focused on helping organizations with their innovation, startup, and communication strategies.
Created by the talent responsible for building the Tech.Co brand (acquired by an international publishing company), we're leveraging decades of experience to help our collaborators further (or create) their brand & accomplish their most important goals.
|
|
Established, LLC is not a broker-dealer and cannot provide assurances and makes no representations or warranties as to the timing or price terms for any purchase or sale of early-stage company equity. Nothing contained in this email constitutes investment, legal, tax or other advice. No information or statements contained in this email should be relied upon in making an investment or different decision. You should review all risks and consult all applicable professionals when making any investment decisions. Information and statements contained within this email and any attachments are solely for informational purposes and does not constitute an offer to sell or a solicitation to buy any securities.
|
|
|
|
|
